

-2-

Amendments to the Claims

Please amend Claims 1, 10, 12, 21 and 22. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (currently amended) A method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide, wherein said peptide is between 12 and 23 amino acids in length, has angiogenic activity and comprises a thrombin receptor binding domain and a serine esterase conserved sequence.
2. (previously presented) The method according to Claim 1 wherein said peptide comprises a thrombin receptor binding domain having the sequence Arg-Gly-Asp-Ala (SEQ ID NO. 1).
3. (original) The method of Claim 2 wherein the serine esterase conserved sequence comprises Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 2).
4. (original) The method of Claim 2 wherein the thrombin derivative peptide comprises the amino acid sequence: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).
5. (original) The method of Claim 1 wherein the thrombin derivative peptide consists of the amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 4).
6. (original) The method of Claim 1 wherein the peptide is administered during or following cardiac surgery.

-3-

7. (original) The method of Claim 2 wherein the peptide is administered by injection into the cardiac tissue.
8. (original) The method of Claim 2 wherein a sustained release formulation comprising the angiogenic thrombin derivative peptide is administered to the cardiac tissue.
9. (original) The method of Claim 8 wherein the sustained release formulation is a polylactic acid/polyglycolic acid microparticles comprising the angiogenic thrombin derivative peptide.
10. (currently amended) A method of stimulating revascularization of cardiac tissue comprising administering to cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide, wherein said peptide is between 12 and 23 amino acids in length, has angiogenic activity and comprises a thrombin receptor binding domain and a serine esterase conserved sequence.
11. (cancelled)
12. (currently amended) A method of inhibiting restenosis in a patient following balloon angioplasty, said method comprising administering to the patient a therapeutically effective amount of an angiogenic thrombin derivative peptide, wherein said peptide is between 12 and 23 amino acids in length, has angiogenic activity and comprises a thrombin receptor binding domain and a serine esterase conserved sequence.
13. (original) The method of Claim 12 wherein the peptide is coated onto a balloon angioplasty catheter.
14. (original) The method of Claim 12 wherein the angiogenic thrombin derivative peptide is administered systemically.

-4-

15. (original) The method of Claim 12 wherein the angiogenic thrombin derivative peptide is administered locally to a balloon induced damaged area of a blood vessel.
16. (original) The method of Claim 12 wherein a stent coated with the angiogenic thrombin derivative peptide is inserted into a blood vessel at a balloon induced damaged area.
17. (previously amended) The method of Claim 12 wherein said peptide comprises a thrombin receptor binding domain having the sequence Arg-Gly-Asp-Ala (SEQ ID NO. 1).
18. (original) The method of Claim 17 wherein the serine esterase conserved sequence comprises Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 2).
19. (original) The method of Claim 17 wherein the thrombin derivative peptide comprises the amino acid sequence: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).
20. (previously presented) The method of Claim 12 wherein the thrombin derivative peptide consists of the amino acid sequence Asp-X₁-Cys-X₂-Gly-Asp-Ser-Gly-Gly-Pro-X₃-Val (SEQ ID NO. 4), wherein X₁ is either Ala or Ser; X₂ is either Glu or Gln; and X₃ is either Phe, Met, Leu, His, or Val.
21. (currently amended) A stent coated with an angiogenic thrombin derivative peptide, wherein said peptide is between 12 and 23 amino acids in length, has angiogenic activity and comprises a thrombin receptor binding domain and a serine esterase conserved sequence.
22. (currently amended) A method of inhibiting vascular occlusion in a patient, said method comprising administering to the patient a therapeutically effective amount of an angiogenic thrombin derivative peptide, wherein said peptide is between 12 and 23 amino

-5-

acids in length, has angiogenic activity and comprises a thrombin receptor binding domain and a serine esterase conserved sequence.

23. (previously presented) The method of Claim 1, wherein the angiogenic thrombin derivative peptide comprises a C-terminal amide.
24. (previously presented) The method of Claim 10, wherein the angiogenic thrombin derivative peptide comprises a C-terminal amide.
25. (previously presented) The method of Claim 12, wherein the angiogenic thrombin derivative peptide comprises a C-terminal amide.
26. (previously presented) The method of Claim 22, wherein the angiogenic thrombin derivative peptide comprises a C-terminal amide.
27. (previously presented) The method of Claim 21, wherein the angiogenic thrombin derivative peptide comprises a C-terminal amide.
28. (previously presented) A method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of a C-terminus amidated peptide comprising the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).
29. (previously presented) A method of stimulating revascularization of cardiac tissue comprising administering to cardiac tissue a therapeutically effective amount of a C-terminus amidated peptide comprising the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).
30. (previously presented) A method of inhibiting restenosis in a patient following balloon angioplasty, said method comprising administering to the patient a therapeutically

-6-

effective amount of a C-terminus amidated peptide comprising the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).

31. (previously presented) A stent coated with a C-terminus amidated peptide comprising the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).
32. (previously presented) A method of inhibiting vascular occlusion in a patient, said method comprising administering to the patient a therapeutically effective amount of a C-terminus amidated peptide comprising the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 3).